July 11, 2022
Lipidor’s Phase III study of AKP02 for treatment of psoriasis now fully recruited, results expected Q3 2022
Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) can today announce that the last patient has been enrolled in the ongoing…